Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28880094 | 1.00 | TAAR1 (0.57) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL23733839 | 1.00 | TAAR1 (0.57) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL23733871 | 0.96 | TAAR1 (0.62) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL27095780 | 0.96 | DPP4 (0.57) | TAAR1DPP4ABCG2ABCC1MEN1 | |
| SCHEMBL25788313 | 0.96 | DPP4 (0.57) | TAAR1DPP4ABCG2ABCC1MEN1 | |
| SCHEMBL23595237 | 0.94 | TAAR1 (0.55) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL27095783 | 0.89 | TAAR1 (0.56) | TAAR1DPP4ESR2MEN1MAPT | |
| SCHEMBL25672123 | 0.88 | TAAR1 (0.53) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL20967338 | 0.87 | TAAR1 (0.45) | TAAR1DPP4ESR2ABCG2ABCC1 | |
| SCHEMBL24961152 | 0.87 | MEN1 (0.50) | TAAR1DPP4ABCG2ABCC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844273-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11844273-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11563183-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-24 | — | — | US | disclosed |
| US-20210367158-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-11-25 | — | — | US | disclosed |
| US-11088331-B2 | — | — | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11563183-B2 | Heterocyclic compound and organic light-emitting device including the same | DDT, PPOX, LEF1 | TAAR1 3612/4885DPP4 1564/4885ESR2 1573/4885 |
| US-11844273-B2 | Heterocyclic compound and organic light-emitting device including the same | DDT, PPOX, LEF1 | TAAR1 3612/4885DPP4 1564/4885ESR2 1573/4885 |
| US-11088331-B2 | — | DDT, PPOX, DBF4 | TAAR1 3540/4885DPP4 1211/4885ESR2 1438/4885 |
| US-20210367158-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | DDT, PPOX, LEF1 | TAAR1 3612/4885DPP4 1564/4885ESR2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.